Antisense Pharma
Cancer drug developer raises $18M in venture financing
Published in Mental Health Business Week, January 7th, 2006
"The investment by the MIG funds provides substantial funding of our advanced clinical program designed to obtain approval of our antisense drug, AP 12009, which we are developing for patients with malignant tumors including brain tumors and pancreatic cancer," explained Reimar Schlingensiepen, founder and COO of Antisense Pharma.
The company has repeatedly received prestigious awards for the innovative potential and goal-directed drug development program as well as corporate management. The lead drug candidate AP 12009 is targeted against...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
More Articles from Mental Health Business Week
- Applied NeuroSolutions, Inc.
Alzheimer-focused company chooses Financial Dynamics as investor relations counsel - Avanir Pharmaceuticals
Neurodex developer reports loss of $0.30 per share - Epilepsy Research Foundation
Epilepsy, Milken foundations announce recipients of epilepsy research grants - American Environmental Products, Inc.
Lighting technology patented for the treatment of seasonal affective disorder - American Society for Cell Biology
Researcher reveals the possible cell biology of learning - Ascension Orthopedics, Inc.
Worldwide distribution agreement signed for Neurolac resorbable nerve guide - More from this issue of Mental Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
